Staurosporine

Drug Profile

Staurosporine

Alternative Names: AM 2282

Latest Information Update: 26 Jul 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Asahi Kasei
  • Class Alkaloids; Anorectics; Antifungals; Antineoplastics; Antiplatelets; Carbazoles
  • Mechanism of Action Platelet aggregation inhibitors; Protein kinase A inhibitors; Protein kinase C inhibitors; Protein kinase G inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Arrhythmias; Cancer; Hypertension; Thrombosis

Most Recent Events

  • 26 Jul 2001 No-Development-Reported for Cancer in Japan (Unknown route)
  • 26 Jun 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 15 Jan 2001 Asahi Chemical is now called Asahi Kasei
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top